References
- Allenspach, K., Wieland, B., Gröne, A., Gaschen, F., 2007: Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J. Vet. Intern. Med., 21, 4, 700‒708. DOI: 10.1892/0891-6640(2007)21[700:ceideo]2.0.co;2.
- Angelucci, E., Malesci, A., Danese, S., 2008: Budesonide: Teaching an old dog new tricks for inflammatory bowel disease treatment. Curr. Med. Chem., 15, 24, 2527‒2535. DOI: 10.2174/092986708785909049.
- Berdyshev, E. V., 2000: Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids, 108, 1‒2, 169‒190. DOI: 10.1016/S0009-3084(00)00195-x.
- Dandrieux, J. R. S., 2016: Inflammatory bowel disease versus chronic enteropathy in dogs: Are they one and the same? J. Small Anim. Pract., 57, 589‒599. DOI: 10.1111/jsap.12588.
- Dupouy-Manescau, N., Neumann, L., Gomes, J., Pas-mans, F., 2024: Updating the classification of chronic inflammatory enteropathies in dogs. Animals, 14, 5, 681. DOI: 10.3390/ani14050681.
- Dye, T. L., McCarthy, R., Lappin, M. R., Long, T., 2013: Randomized, controlled trial of budesonide and prednisone for the treatment of idiopathic inflammatory bowel disease in dogs. J. Vet. Intern. Med., 27, 6, 1385‒1391. DOI: 10.1111/jvim.12195.
- Fenimore, A., Martin, L., Lappin, M. R., 2017: Evaluation of metronidazole with and without Enterococcus faecium SF68 in shelter dogs with diarrhoea. Topics Compan. Anim. Med., 32, 3, 100‒103. DOI: 10.1053/j.tcam.2017.11.001.
- Jergens, A. E., Heilmann, R. M., 2022: Canine chronic enteropathy, current state-of-the-art and emerging concepts. Front. Vet. Sci., 9, 923013. DOI: 10.3389/fvets.2022.923013.
- Hodel, S., Brugger, D., Kook, P. H., 2024: Long-term evaluation of the initial response to therapy in 60 dogs with chronic inflammatory enteropathy. J. Vet. Intern. Med., 38, 2444‒2453. DOI: 10.1111/jvim.17161.
- Kathrani, A., 2021: Dietary and nutritional approaches to the management of chronic enteropathy in dogs and cats. Vet. Clin. North Am. Small Anim. Pract., 51, 1, 123136. DOI: 10.1016/j.cvsm.2020.09.005.
- Klein, T. W., Newton, C., Friedman, H., 1998: Cannabinoid receptors and immunity. Immunol. Today, 19, 8, 373‒381. DOI: 10.1016/S0167-5699(98)01300-0.
- Klein, T. W., Newton, C., Zhong, Y., Friedman, H., 2000: The cannabinoid system and cytokine network. Proc. Soc. Exp. Bio. Med., 225, 1, 1‒8. DOI: 10.1111/j.1525-1373.2000.22501.x.
- Lowe, H., Smith, J., Jones, P., 2021: The endocannabinoid system: A potential target for the treatment of various diseases. Int. J. Mol. Sci., 22, 17, 9472. DOI: 10.3390/ ijms22179472.
- Massa, F., Monory, R., Zimmer, A., 2004: The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest., 113, 8, 1202‒1209. DOI: 10.1172/JCI19465.
- Menozzi, A., Dall’Aglio, M., Quintavalla, F., Magar, A., 2016: Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: A randomized trial. BMC Vet. Res., 12, 217. DOI: 10.1186/s12917-016-0851-0.
- Pietra, M., D’Angelo, A., De Rosa, G., 2013: Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. Am. J. Vet. Res., 74, 1, 78‒83. DOI: 10.2460/ajvr.74.1.78.
- Rychlik, A., Tyll, S., Krištof, M., 2016: Clinical, endoscopic and histopathological evaluation of the efficacy of budesonide in the treatment of inflammatory bowel disease in dogs. Pol. J. Vet. Sci., 19, 1, 159‒164. DOI: 10.1515/pjvs-2016-0020.
- Seow, C. H., Kwan, K., 2008: Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev., 3, CD000296. DOI: 10.1002/14651858.CD000296.pub3.
- Stroup, S. T., Oliver, J. A., Weeks, R. C. S., Anderson, N. K., 2006: Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. Am. J. Vet. Res., 67, 7, 1173‒1178. DOI: 10.2460/ajvr.67.7.1173.
- Suchodolski, J. S., 2016: Diagnosis and interpretation of intestinal dysbiosis in dogs and cats. Vet. J., 215, 30‒37. DOI: 10.1016/j.tvjl.2016.04.011.
- Sun, X., Chen, H., Zhang, H., Li, J., 2015: Compare the efficacy of inhaled budesonide and systemic methylpredniso-lone on systemic inflammation of AECOPD. Pul. Pharmacol. Ther., 31, 111‒116. DOI: 10.1016/j.pupt.2014.09.004.
- Szweda, M., Zareba, K. Lewandowski, K., 2017: The effect of budesonide on the expression of Ki-67 and PCNA and the apoptotic index in dogs with inflammatory bowel disease. Pol. J. Vet. Sci., 20, 4. DOI: 10.1515/pjvs-2017-0094.
- Tizard, I. R., Jones, S. W., 2018: The microbiota regulates immunity and immunologic diseases in dogs and cats. Vet. Clin. North Am. Small Anim. Pract., 48, 2, 307‒322. DOI: 10.1016/j.cvsm.2017.10.008.
- Tumulty, J. W., Bockstahler, B., LaBranche, A., 2004: Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. J. Am. Anim. Hosp. Assoc., 40, 2, 120‒123. DOI: 10.5326/0400120.
- Xia, J., Cui, Y., Guo, Y., Liu, Y., Deng, B., Han, S., 2024: The function of probiotics and prebiotics on canine intestinal health and their evaluation criteria. Microorganisms, 12, 6, 1248. DOI: 10.3390/microorganisms12061248.
- Zareie, M., Cohen, S. R., Li, J. Q., Palmer, H. R., Chang, E. B., 1999: Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. J. Pharmacol. Exp. Ther., 289, 3, 1245‒1249.